Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017

Published: Jun, 2017 | Pages: 258 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 16, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Gastrointestinal Stromal Tumor (GIST) - Overview 8
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 27
AB Science SA 27
Advanced Accelerator Applications SA 27
Advenchen Laboratories LLC 28
Ariad Pharmaceuticals Inc 28
Arog Pharmaceuticals Inc 29
ArQule Inc 29
Array BioPharma Inc 30
Astex Pharmaceuticals Inc 30
Blueprint Medicines Corp 31
Boston Biomedical Inc 31
Calithera Biosciences Inc 32
Celldex Therapeutics Inc 32
Chipscreen Biosciences Ltd 33
CytRx Corp 33
Deciphera Pharmaceuticals LLC 34
Exelixis Inc 34
F. Hoffmann-La Roche Ltd 35
Hanmi Pharmaceuticals Co Ltd 35
Horizon Pharma Plc 36
Immunicum AB 36
Jiangsu Hengrui Medicine Co Ltd 37
Natco Pharma Ltd 37
Nerviano Medical Sciences Srl 38
Novartis AG 38
Omeros Corp 39
Pharma Mar SA 39
Plexxikon Inc 40
Rhizen Pharmaceuticals SA 40
Taiho Pharmaceutical Co Ltd 41
Gastrointestinal Stromal Tumor (GIST) - Drug Profiles 42
aldoxorubicin hydrochloride - Drug Profile 42
amcasertib - Drug Profile 59
apatinib - Drug Profile 62
ARQ-092 - Drug Profile 67
binimetinib - Drug Profile 70
BLU-285 - Drug Profile 79
buparlisib hydrochloride - Drug Profile 83
cabozantinib s-malate - Drug Profile 89
CB-839 - Drug Profile 108
CDX-0158 - Drug Profile 116
CHMFLKIT-110 - Drug Profile 119
crenolanib besylate - Drug Profile 120
CS-2164 - Drug Profile 124
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 125
DCC-2618 - Drug Profile 133
everolimus - Drug Profile 135
HM-95573 - Drug Profile 147
interferon gamma-1b - Drug Profile 149
Intuvax - Drug Profile 154
masitinib - Drug Profile 160
nilotinib - Drug Profile 176
NMSP-088 - Drug Profile 182
NRCAN-019 - Drug Profile 183
onalespib - Drug Profile 185
Peptide to Antagonize GRPR for Oncology - Drug Profile 189
pexidartinib - Drug Profile 190
PLX-9486 - Drug Profile 195
PM-184 - Drug Profile 196
ponatinib hydrochloride - Drug Profile 198
SF-1126 - Drug Profile 214
SHR-1020 - Drug Profile 216
Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile 218
Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile 219
TAS-116 - Drug Profile 220
TGR-1202 - Drug Profile 221
vemurafenib - Drug Profile 230
WBZ-4 - Drug Profile 237
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 238
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 239
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 240
Featured News & Press Releases 240
Appendix 255
Methodology 255
Coverage 255
Secondary Research 255
Primary Research 255
Expert Panel Validation 255
Contact Us 255
Disclaimer 256

List of Tables

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advanced Accelerator Applications SA, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories LLC, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals Inc, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals Inc, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule Inc, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals Inc, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corp, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical Inc, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences Inc, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Celldex Therapeutics Inc, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by CytRx Corp, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Exelixis Inc, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Ltd, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences Srl, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corp, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Pharma Mar SA, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2017
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2017